Biotech

All Articles

ArsenalBio raises $325M, pivots off of previous lead possession

.Collection Biosciences is actually carrying on up. The tissue therapy company has actually added $3...

Lilly- supported weight-loss biotech files IPO

.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has filed to ...

Aelis' cannabis usage medicine fails phase 2b, steering Indivior to reconsider $100M alternative

.Aelis Farma's hopes of securing an easy, favorable selection on a $one hundred million possibility ...

ProKidney stops stage 3 trial not needed for tissue therapy permission

.ProKidney has stopped one of a set of period 3 trials for its tissue therapy for renal illness afte...

Vaxcyte rises on 'magnificent' 31-valent PCV succeed versus Pfizer

.Vaxcyte introduced what analysts named "stunning" stage 1/2 information for its 31-valent pneumococ...

Recursion's brain disease test presents insufficient documentation of effectiveness

.Recursion has stumbled through a very early examination of its tech-enabled strategy to drug discov...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Contact it a scenario of excellent chemistry: Acepodia, a biotech based on Nobel Prize-winning scie...

Praxis epilepsy medication decreases seizures in phase 2 trial

.Practice Precision Medicines has actually scored one more midphase gain in epilepsy this year, alon...

Three directors surrender as Dyne articles combined information for DMD prospect

.After leaving a scientific hold numerous years back, Dyne Rehab has revealed brand new period 1/2 i...

Arrowhead fires off phase 3 information in rare metabolic illness before market encounter Ionis

.Arrowhead Pharmaceuticals has presented its give in front of a potential face-off along with Ionis,...